Changzhou Qianhong Biopharma Co Ltd (002550) — Net Asset Quality Index
Changzhou Qianhong Biopharma Co Ltd (002550) has a Net Asset Quality Index of 88.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.23 Billion minus total liabilities of CN¥379.82 Million yields net assets of CN¥2.85 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Changzhou Qianhong Biopharma Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Changzhou Qianhong Biopharma Co Ltd Net Asset Quality Index Over Time (2007–2025)
This chart shows how Changzhou Qianhong Biopharma Co Ltd's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 88.2%, representing net assets of CN¥2.85 Billion against total assets of CN¥3.23 Billion CNY. Explore cash flow conversion of Changzhou Qianhong Biopharma Co Ltd to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Changzhou Qianhong Biopharma Co Ltd (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 002550 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 89.6% | CN¥2.77 Billion | CN¥3.09 Billion | CN¥320.64 Million | ▲ +0.7 pp |
| 2024 | 88.9% | CN¥2.52 Billion | CN¥2.83 Billion | CN¥313.87 Million | ▼ -0.5 pp |
| 2023 | 89.4% | CN¥2.47 Billion | CN¥2.77 Billion | CN¥292.17 Million | ▲ +2.7 pp |
| 2022 | 86.7% | CN¥2.43 Billion | CN¥2.81 Billion | CN¥372.53 Million | ▲ +2.3 pp |
| 2021 | 84.4% | CN¥2.12 Billion | CN¥2.51 Billion | CN¥390.24 Million | ▲ +0.2 pp |
| 2020 | 84.2% | CN¥2.07 Billion | CN¥2.45 Billion | CN¥386.35 Million | ▲ +4.7 pp |
| 2019 | 79.5% | CN¥2.33 Billion | CN¥2.93 Billion | CN¥601.65 Million | ▼ -0.4 pp |
| 2018 | 79.9% | CN¥2.54 Billion | CN¥3.18 Billion | CN¥640.11 Million | ▼ -0.7 pp |
| 2017 | 80.6% | CN¥2.45 Billion | CN¥3.04 Billion | CN¥591.41 Million | ▲ +0.7 pp |
| 2016 | 79.9% | CN¥2.42 Billion | CN¥3.03 Billion | CN¥609.33 Million | ▼ -1.1 pp |
| 2015 | 81.0% | CN¥2.29 Billion | CN¥2.83 Billion | CN¥538.67 Million | ▼ -11.3 pp |
| 2014 | 92.3% | CN¥2.13 Billion | CN¥2.31 Billion | CN¥178.06 Million | ▼ -3.1 pp |
| 2013 | 95.4% | CN¥1.97 Billion | CN¥2.07 Billion | CN¥95.77 Million | ▼ -1.6 pp |
| 2012 | 97.0% | CN¥1.87 Billion | CN¥1.93 Billion | CN¥58.54 Million | ▲ +1.7 pp |
| 2011 | 95.3% | CN¥1.77 Billion | CN¥1.85 Billion | CN¥87.07 Million | ▲ +19.9 pp |
| 2010 | 75.4% | CN¥413.78 Million | CN¥548.53 Million | CN¥134.75 Million | ▲ +29.8 pp |
| 2009 | 45.6% | CN¥243.68 Million | CN¥533.87 Million | CN¥290.19 Million | ▼ -10.0 pp |
| 2008 | 55.6% | CN¥217.99 Million | CN¥391.74 Million | CN¥173.75 Million | ▼ -17.7 pp |
| 2007 | 73.3% | CN¥211.61 Million | CN¥288.56 Million | CN¥76.95 Million | — |